News Headlines

  1. Almac Group Announces Publication Of Prostate Cancer Metastatic Assay Validation
    4/20/2017

    Almac Group’s Diagnostics business unit recently announced the Journal of European Urology has published results relating to its Prostate Cancer Metastatic Assay. The publication demonstrates the assay can be used to analyse primary prostate cancer FFPE samples to identify a molecular subgroup with a high risk of developing distant metastases.

  2. PPD Heroes Advocate For Clinical Research To Improve Patient Health
    4/20/2017

    Pharmaceutical Product Development, LLC (PPD) recently announced the kickoff of its 2017 educational campaign to raise awareness about the life-changing impact of clinical research, featuring a team of PPD Heroes who share their personal stories to inspire hope.

  3. Lion Biotechnologies Announces Strategic Alliance With MD Anderson Cancer Center To Conduct Clinical Trials Of TILs In Multiple Solid Tumors
    4/19/2017

    Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology and The University of Texas MD Anderson Cancer Center, today announced a multi-year strategic alliance agreement involving multi-arm clinical trials to evaluate the safety and efficacy of TIL therapy in ovarian cancer, various sarcomas, and pancreatic cancer.

  4. Veeva Introduces Vault SiteExchange To Simplify Document Exchange In Clinical Trials
    4/19/2017

    Veeva Systems recently announced Veeva Vault SiteExchange, a cloud application that allows life sciences companies, CROs, and sites to easily access and exchange information during clinical trial execution.

  5. TransCelerate Selects Veeva Vault SiteExchange
    4/19/2017

    Veeva Systems and TransCelerate BioPharma Inc., a non-profit organization with membership comprised of global biopharmaceutical companies, recently announced TransCelerate selected Veeva Vault SiteExchange for the Shared Investigator Platform (SIP), a platform that facilitates investigative site collaboration with multiple clinical trial sponsors.

  6. Vical Completes Target Enrollment In Its Phase 2 Therapeutic HSV-2 Vaccine Trial
    4/19/2017

    Vical Incorporated (Nasdaq:VICL) announced today that it has completed the target enrollment of 225 subjects in a Phase 2 trial of its therapeutic bivalent vaccine for herpes simplex virus type 2 (HSV-2), the leading cause of recurrent genital herpes.

  7. Plasticell And Kings College London To Collaborate In Trials Of Blood Platelet Substitute
    4/19/2017

    Plasticell, a developer of cell therapies including hematopoietic cell replacement therapies, recently announced it has partnered with Kings College London to progress preclinical trials of its artificial blood platelet product, manufactured from pluripotent stem cells.

  8. Motif Bio Announces Positive Results For Iclaprim, In The REVIVE-1 Phase 3 Study
    4/18/2017

    Motif Bio plc (Motif) (NASDAQ:MTFB), (NASDAQ:MTFBW), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced positive topline results from REVIVE-1, a global Phase 3 clinical trial of its investigational drug candidate iclaprim in patients with acute bacterial skin and skin structure infections (ABSSSI).

  9. Cellectar Biosciences Receives Japanese Patent For CLR 131 And CLR 125 For The Treatment Of Cancer Stem Cells
    4/18/2017

    Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, today announces the Japanese Patent Office has granted a method of use patent for two of the company’s phospholipid drug conjugates (PDCs), CLR 131, the company’s lead compound, and CLR 125, each in combination with radiation and/or other therapies to treat cancer stem cells.

  10. Prima BioMed Receives Approval For Third Cohort Of Phase I Melanoma Trial
    4/18/2017

    Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima” or the “Company”) today announced that approval has been granted for the third cohort of its Phase I clinical trial for IMP321 in combination with KEYTRUDA® being conducted in Australia.